1043 Intratumoral mRNA IL-12 can induce a dose dependent immunostimulatory effect within tumor microenvironment in patients with advanced solid tumors

• Vivek Subbiah,
• Dmitriy Zamarin,
• Omid Hamid,
• Igor Feldman,
• Thomas Marron,
• Yuling Wu,
• Inderjit Mehmi,
• Michael Abadier,
• Analia Azaro,
• Anthony El-Khoueiry,
• Eduardo Castañón Álvarez,
• Jacky Chow,
• Praveen Aanur,
• Khanh Do,
• Vasudha Sehgal,
• Sandip P Patel,
• Benedito Carneiro,
• Linh Van,
• Nicholas Durham,
• Xiaoru Chen,
• Paula G Fraenkel,
• Arjun Oberoi

Affiliations

Vivek Subbiah

2MD Anderson Cancer Center, Houston, TX, USA

Dmitriy Zamarin

3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Omid Hamid

3The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA

Igor Feldman

1Moderna, Cambridge, MA, USA

Thomas Marron

4Mount Sinai Hospital, New York, NY, USA

Yuling Wu

AstraZeneca, Gaithersburg, Maryland, USA

Inderjit Mehmi

11Cedars Sinai Marina Del Rey Hospital, Los Angeles, CA, USA

Michael Abadier

Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

Analia Azaro

4Vall d’Hebron University Hospital, Barcelona, Spain

Anthony El-Khoueiry

2USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Eduardo Castañón Álvarez

8Clínica Universidad de Navarra, Madrid, Spain

Jacky Chow

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Praveen Aanur

11 Moderna Inc., Cambridge, MA, USA

Khanh Do

19Moderna Inc., Cambridge, MA, USA

Vasudha Sehgal

11 Moderna Inc., Cambridge, MA, USA

Sandip P Patel

8University of California, San Diego, La Jolla, CA, USA

Benedito Carneiro

2Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Linh Van

1Moderna, Cambridge, MA, USA

Nicholas Durham

2AstraZeneca, Gaithersburg, MD, USA

Xiaoru Chen

2AstraZeneca, Gaithersburg, MD, USA

Paula G Fraenkel

3AstraZeneca, Waltham, MA, USA

Arjun Oberoi

12Vall d’Hebron Institute of Oncology, Barcelona, Spain